Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ISPPEA

- PMLiVE

BMS confirms COVID-19 vaccine immune response in Zeposia-treated MS patients

Over 92% of patients in the analyses mounted a serological response following vaccination

Biogen Idec building

Biogen to pay $900m to settle whistleblower’s MS drug kickback lawsuit

For pursuing the case, the former employee will receive about $250m

- PMLiVE

Tiziana’s Foralumab shows promise in second patient with secondary progressive MS

MS affects around 700,000 people in Europe and approximately 2.5 million people worldwide

- PMLiVE

Tiziana announces Brigham and Women’s hospital will receive ALS Association grant

ALS affects as many as 30,000 people in the US

- PMLiVE

Sanofi halts recruitment for trials assessing MS treatment

The pause in enrolment follows advice issued by the Independent Data Monitoring Committee

- PMLiVE

Sandoz’s application for MS biosimilar accepted by FDA

The proposed ‘first-of-a-kind’ biosimilar matched the reference medicine, Biogen’s Tysabri, in terms of efficacy, safety and immunogenicity

- PMLiVE

Biogen and Happify Health team up to create digital platform for MS patients

There are over 2.3 million people living with MS worldwide, with women being more likely to develop the condition than men

- PMLiVE

Innovative Trials partners with MS Society

UK-based patient recruitment company announces its annual charity partnership in support of multiple sclerosis

Innovative Trials

- PMLiVE

Biogen and MedRhythms sign deal worth over $120m for digital therapeutics for MS patients

The collaboration is focused on improving MS patients’ mobility and walking

Roche Basel Switzerland

Roche shares new positive Ocrevus data for MS patients

The CONSONANCE trial showed treatment with Ocrevus resulted in a majority of patients experiencing no disease progression

Biogen Idec building

SMC approves Biogen’s Vumerity for patients with multiple sclerosis

The new, at-home oral treatment has been developed for adults in Scotland living with relapsing-remitting multiple sclerosis

- PMLiVE

Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS

The data presented at ECTRIMS 2021 reinforces the efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links